Discounted Cash Flow Rating

Neutral

Return on Equity Rating

Strong Sell

Debt to Equity Rating

Neutral

Price to Earnings Rating

Neutral

Analyst Rating

Sell

Simple Moving Average

Neutral

Exponential Moving Average

Neutral

Relative Strength Index

Strong Buy

Standard Deviation

Sell

Williams %R

Strong Buy

Average Directional Index

Neutral

Insider Trading

Neutral

Wall Street Data Solutions Rating

Neutral

B

NGM Biopharmaceuticals, Inc. Common Stock (NGM)

Pharmaceutical Preparations

https://www.ngmbio.com

NGM Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapeutics based on scientific understanding of key biological pathways for the treatment of cardio-metabolic, liver, oncologic and ophthalmic diseases. The company's products include NGM282 (aldafermin), NGM313 (MK-3655), NGM120, NGM120, NGM621, and NGM395, all these are focused on NASH, diabetes, oncology, AMD and metabolic disease.

333 OYSTER POINT BOULEVARD
SOUTH SAN FRANCISCO, CA

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

04/04/2019

Market Cap

128,532,096

Shares Outstanding

82,720,000

Weighted SO

82,715,507

Total Employees

N/A

Upcoming Earnings

N/A

Similar Tickers

NLTX --.--%

TIL --.--%

ACHL --.--%

NXTC --.--%

ASMB --.--%

ERAS --.--%

IPSC --.--%

KROS --.--%

GLUE --.--%

Beta

1.2610

Last Div

0.0000

Range

0.6002-4.69

Chg

-0.0200

Avg Vol

1070739

Mkt Cap

128532096

Exch

NASDAQ

Country

US

Phone

650 243 5555

DCF Diff

0.9274

DCF

0.6126

Div Yield

0.0000

P/S

29.0994

EV Multiple

-0.4652

P/FV

0.8579

Div Yield %

0.0000

P/E

-0.9120

PEG

-0.0698

Payout

0.0000

Current Ratio

7.7906

Quick Ratio

7.3324

Cash Ratio

2.9289

DSO

4.7928

DIO

0.0000

Op Cycle

4.7928

DPO

334.2844

CCC

-329.4916

Gross Margin

0.2628

Op Margin

-34.2909

Pretax Margin

-32.2334

Net Margin

-31.6568

Eff Tax Rate

0.0000

ROA

-0.8280

ROE

-0.7646

ROCE

-1.0180

NI/EBT

0.9821

EBT/EBIT

0.9400

EBIT/Rev

-34.2909

Debt Ratio

0.0000

D/E

0.0000

LT Debt/Cap

0.0000

Total Debt/Cap

0.0000

Int Coverage

0.0000

CF/Debt

0.0000

Equity Multi

1.1361

Rec Turnover

76.1552

Pay Turnover

1.0919

Inv Turnover

0.0000

FA Turnover

0.6280

Asset Turnover

0.0262

OCF/Share

-1.5966

FCF/Share

-1.6117

Cash/Share

1.7775

OCF/Sales

-29.9303

FCF/OCF

1.0095

CF Coverage

0.0000

ST Coverage

0.0000

CapEx Coverage

-105.5927

Div&CapEx Cov

-105.5927

P/BV

0.8579

P/B

0.8579

P/S

29.0994

P/E

-0.9120

P/FCF

-0.9631

P/OCF

-0.9646

P/CF

-0.9646

PEG

-0.0698

P/S

29.0994

EV Multiple

-0.4652

P/FV

0.8579

DPS

0.0000

Latest Headlines (EST)

GlobeNewswire Inc. Jun 05, 02:31 Arctic Wolf Expands into Singapore to Meet Rising Demand for AI-Powered Security Operations GlobeNewswire Inc. Jan 17, 16:47 NGM Bio to Participate in the B. Riley Securities 4th Annual Oncology Conference Benzinga Nov 22, 12:00 B. Riley Securities Maintains Buy Rating for NGM Biopharmaceuticals: Here's What You Need To Know GlobeNewswire Inc. Nov 13, 09:45 NGM Bio Presents Positive Phase 2b Results from the ALPINE 4 Trial of Aldafermin in Patients with Compensated Cirrhosis (F4) Due to NASH at AASLD The Liver Meeting® Zacks Investment Research Nov 08, 21:30 NeoGames S.A. (NGMS) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates Zacks Investment Research Nov 08, 21:30 NeoGames S.A. (NGMS) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates Zacks Investment Research Nov 02, 17:25 NGM Biopharmaceuticals (NGM) Reports Q3 Loss, Misses Revenue Estimates Seeking Alpha Nov 01, 00:36 Spirit-JetBlue And 14 Other Opportunities In The Merger Arbitrage Space

Revenue Product Segmentation